ATE498693T1 - Marker zur prognose der reaktion auf therapie bzw. der überlebensrate von brustkrebspatienten - Google Patents
Marker zur prognose der reaktion auf therapie bzw. der überlebensrate von brustkrebspatientenInfo
- Publication number
- ATE498693T1 ATE498693T1 AT04029486T AT04029486T ATE498693T1 AT E498693 T1 ATE498693 T1 AT E498693T1 AT 04029486 T AT04029486 T AT 04029486T AT 04029486 T AT04029486 T AT 04029486T AT E498693 T1 ATE498693 T1 AT E498693T1
- Authority
- AT
- Austria
- Prior art keywords
- predicting
- response
- markers
- therapy
- breast cancer
- Prior art date
Links
- 230000004083 survival effect Effects 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000030933 DNA methylation on cytosine Effects 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03090432 | 2003-12-11 | ||
| EP04090041 | 2004-02-10 | ||
| EP04090127 | 2004-04-01 | ||
| EP04013328 | 2004-06-05 | ||
| EP04090380 | 2004-09-30 | ||
| EP04027213 | 2004-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE498693T1 true ATE498693T1 (de) | 2011-03-15 |
Family
ID=34637445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04029486T ATE498693T1 (de) | 2003-12-11 | 2004-12-13 | Marker zur prognose der reaktion auf therapie bzw. der überlebensrate von brustkrebspatienten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9017944B2 (de) |
| EP (1) | EP1692316A2 (de) |
| JP (2) | JP2007513621A (de) |
| AT (1) | ATE498693T1 (de) |
| AU (3) | AU2004237861B2 (de) |
| CA (2) | CA2549852A1 (de) |
| DE (1) | DE602004031405D1 (de) |
| WO (1) | WO2005059172A2 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| CA2500255A1 (en) * | 2002-10-01 | 2004-04-29 | Epigenomics Ag | Method and nucleic acids for the treatment of breast cell proliferative disorders |
| JP2007513621A (ja) * | 2003-12-11 | 2007-05-31 | エピゲノミクス アーゲー | 乳房細胞増殖性障害の改良された処置のための方法および核酸 |
| EP1961827A3 (de) * | 2004-07-18 | 2008-09-17 | Epigenomics AG | Epigenetische Verfahren und Nukleinsäuren für den Nachweis von proliferativen Erkrankungen von Mammazellen |
| CA2593546A1 (en) | 2004-12-02 | 2006-07-06 | Epigenomics Ag | Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders |
| CA2606296C (en) | 2005-04-15 | 2019-05-21 | Epigenomics Ag | Methods and nucleic acids for analyses of cellular proliferative disorders |
| WO2006131391A1 (en) * | 2005-06-10 | 2006-12-14 | Epigenomics Ag | Prognostic assay for prediction of treatment response and/or survival of breast cell proliferative disorder patients |
| WO2007003397A2 (en) * | 2005-07-01 | 2007-01-11 | Epigenomics Ag | Method and nucleic acids for the improved treatment of cancers |
| WO2007047699A1 (en) * | 2005-10-17 | 2007-04-26 | Epigenomics Ag | Method and nucleic acids for the improved treatment of breast cancers |
| WO2007085497A2 (en) * | 2006-01-30 | 2007-08-02 | Epigenomics Ag | Markers for the prediction of outcome of anthracycline treatment |
| US8068994B2 (en) * | 2007-07-27 | 2011-11-29 | Wayne State University | Method for analyzing biological networks |
| WO2009037635A2 (en) * | 2007-09-17 | 2009-03-26 | Koninklijke Philips Electronics N. V. | Method for the analysis of breast cancer disorders |
| AU2008312457B2 (en) * | 2007-10-19 | 2014-04-17 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
| US20120101023A1 (en) * | 2009-04-20 | 2012-04-26 | Erasmus University Medical Center Rotterdam | Method of diagnosing bladder cancer |
| WO2011002024A1 (ja) * | 2009-06-30 | 2011-01-06 | シスメックス株式会社 | 生体試料中の上皮性癌由来の細胞の存否を判定するための方法、分子マーカー及びキット |
| WO2011112947A1 (en) * | 2010-03-12 | 2011-09-15 | Cenetron Diagnostics Llc | Methods and compositions comprising nucleic acid polymerization enhancers |
| EP2505665A1 (de) * | 2011-03-31 | 2012-10-03 | Queen Mary And Westfield College, University Of London | Krebsmarker |
| EP2707506B1 (de) * | 2011-05-12 | 2018-07-11 | The Johns Hopkins University | Verfahren zum nachweis von krebs durch allgemeinen stabilitätsverlust epigenetischer domänen und zusammensetzungen dafür |
| JP6397762B2 (ja) | 2011-07-08 | 2018-09-26 | エピゲノミクス アーゲー | がん被験体の予後を決定する方法及び核酸 |
| US10316361B2 (en) | 2011-07-15 | 2019-06-11 | The John Hopkins University | Genome-wide methylation analysis and use to identify genes specific to breast cancer hormone receptor status and risk of recurrence |
| GB201204785D0 (en) | 2012-03-19 | 2012-05-02 | Queen Mary & Westfield College | Method for determining prognosis of prostate cancer in a subject |
| ES2859645T3 (es) | 2013-03-14 | 2021-10-04 | Mayo Found Medical Education & Res | Detección de neoplasia |
| WO2016160454A1 (en) | 2015-03-27 | 2016-10-06 | Exact Sciences Corporation | Detecting esophageal disorders |
| US20170211035A1 (en) | 2016-01-25 | 2017-07-27 | American Sterilizer Company | Biological indicators |
| EP3421609B1 (de) * | 2016-02-24 | 2022-03-02 | FUJIFILM Corporation | Verfahren zur quantifizierung der chromosomenzahl |
| EP3497220A4 (de) | 2016-08-10 | 2020-04-01 | Grail, Inc. | Verfahren zur herstellung von dual-indexierten dna-bibliotheken zur bisulfitumwandlungssequenzierung |
| US11466323B2 (en) * | 2017-07-13 | 2022-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Dual-probe digital droplet PCR strategy for specific detection of tissue-specific circulating DNA molecules |
| EP3776135A4 (de) * | 2018-03-26 | 2021-12-22 | Rush University Medical Center | Verfahren zur behandlung mit einer genexpressionssignatur zur vorhersage der antwort von auf her2-gerichteten therapien |
| WO2020136602A1 (en) | 2018-12-27 | 2020-07-02 | 3M Innovative Properties Company | A multilayer test pack for sterilization monitoring |
| US20220162709A1 (en) * | 2019-04-03 | 2022-05-26 | Mayo Foundation For Medical Education And Research | Detecting pancreatic ductal adenocarcinoma in plasma |
| WO2020252721A1 (en) * | 2019-06-20 | 2020-12-24 | The Johns Hopkins University | Dna methylation markers and their use in differentiation of suspected cancerous lymph node biopsy samples |
| KR102923870B1 (ko) | 2019-09-02 | 2026-02-06 | 주식회사 시선바이오머티리얼스 | 신규한 pna 올리고머, 이의 dna 메틸화 검출용도 및 이를 이용한 dna 메틸화 검출방법 |
| CN115910365B (zh) * | 2022-11-16 | 2024-02-13 | 华中科技大学同济医学院附属同济医院 | Eos-CRSwNP术前难治性评估模型的构建方法及预测系统 |
| US20240410006A1 (en) * | 2023-06-12 | 2024-12-12 | Tru Diagnostics, Inc. | Method for Predicting Health of a Human Subject |
| CN117070633A (zh) * | 2023-10-05 | 2023-11-17 | 上海奕谱生物科技有限公司 | DNA甲基化标志物TAGMe-4及其在肿瘤检测中的用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| SE501439C2 (sv) | 1993-06-22 | 1995-02-13 | Pharmacia Lkb Biotech | Sätt och anordning för analys av polynukleotidsekvenser |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| EP0889122A3 (de) | 1993-11-30 | 1999-03-03 | McGILL UNIVERSITY | DNA Methyltransferase Inhibierung |
| US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US5871917A (en) | 1996-05-31 | 1999-02-16 | North Shore University Hospital Research Corp. | Identification of differentially methylated and mutated nucleic acids |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| US5958773A (en) | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| US6596488B2 (en) | 2000-03-30 | 2003-07-22 | City Of Hope | Tumor suppressor gene |
| AUPR142500A0 (en) | 2000-11-13 | 2000-12-07 | Human Genetic Signatures Pty Ltd | A peptide nucleic acid-based assay for the detection of specific nucleic acid sequences |
| US6756200B2 (en) * | 2001-01-26 | 2004-06-29 | The Johns Hopkins University School Of Medicine | Aberrantly methylated genes as markers of breast malignancy |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| DE10228917A1 (de) | 2002-06-24 | 2004-01-22 | Epigenomics Ag | Vorrichtung zur Handhabung von Flüssigkeiten in einer Mehrzahl von Kanälen |
| CA2500255A1 (en) * | 2002-10-01 | 2004-04-29 | Epigenomics Ag | Method and nucleic acids for the treatment of breast cell proliferative disorders |
| JP2007513621A (ja) * | 2003-12-11 | 2007-05-31 | エピゲノミクス アーゲー | 乳房細胞増殖性障害の改良された処置のための方法および核酸 |
| US20090203639A1 (en) * | 2005-04-15 | 2009-08-13 | Oncomethylome Sciences, Inc. | Methylation Markers for Diagnoses and Treatment of Cancers |
-
2004
- 2004-12-13 JP JP2006543511A patent/JP2007513621A/ja active Pending
- 2004-12-13 EP EP04820431A patent/EP1692316A2/de not_active Withdrawn
- 2004-12-13 AU AU2004237861A patent/AU2004237861B2/en not_active Ceased
- 2004-12-13 DE DE200460031405 patent/DE602004031405D1/de not_active Expired - Lifetime
- 2004-12-13 WO PCT/EP2004/014170 patent/WO2005059172A2/en not_active Ceased
- 2004-12-13 AT AT04029486T patent/ATE498693T1/de not_active IP Right Cessation
- 2004-12-13 CA CA002549852A patent/CA2549852A1/en not_active Abandoned
- 2004-12-13 CA CA 2487578 patent/CA2487578A1/en not_active Abandoned
- 2004-12-13 AU AU2004298537A patent/AU2004298537A1/en not_active Abandoned
- 2004-12-13 US US10/582,705 patent/US9017944B2/en active Active
- 2004-12-13 JP JP2004360619A patent/JP2005204651A/ja not_active Withdrawn
-
2010
- 2010-03-16 AU AU2010201017A patent/AU2010201017A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005059172A3 (en) | 2005-12-08 |
| AU2004237861A1 (en) | 2005-06-30 |
| CA2487578A1 (en) | 2005-06-11 |
| AU2010201017A1 (en) | 2010-04-08 |
| WO2005059172A2 (en) | 2005-06-30 |
| US9017944B2 (en) | 2015-04-28 |
| JP2005204651A (ja) | 2005-08-04 |
| US20080254447A1 (en) | 2008-10-16 |
| DE602004031405D1 (de) | 2011-03-31 |
| CA2549852A1 (en) | 2005-06-30 |
| AU2004237861B2 (en) | 2010-04-29 |
| JP2007513621A (ja) | 2007-05-31 |
| AU2004298537A1 (en) | 2005-06-30 |
| EP1692316A2 (de) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004031405D1 (de) | Marker zur Prognose der Reaktion auf Therapie bzw. der Überlebensrate von Brustkrebspatienten | |
| ATE437962T1 (de) | Verfahren für die behandlung von proliferativen erkrankungen von brustzellen | |
| MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
| NZ577805A (en) | Genetic markers for risk management of cardiac arrhythmia | |
| WO2007140958A3 (en) | Method for identifying whether a patient will be responder or not to immunotherapy | |
| NZ587903A (en) | Susceptibility for lung cancer using the polymorphic marker rs1051730 | |
| WO2006133420A3 (en) | Treatment of patients with cancer therapy | |
| WO2005116259A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
| NO20081884L (no) | Modulasjon av glukagonreseptorekspresjon | |
| AU2003293141A8 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| WO2004078035A3 (en) | Expression profiles for breast cancer and methods of use | |
| Griner et al. | Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway | |
| WO2006133361A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
| AR049564A1 (es) | Metodos para la evaluacion y tratamiento del cancer | |
| GB0228337D0 (en) | Replication protein | |
| JP2014525270A5 (de) | ||
| DE602004032329D1 (de) | Marker für präkanzeröse und kanzeröse zellen sowie verfahren zur störung der zellproliferation darin | |
| PL1618195T3 (pl) | Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinowe | |
| WO2005039645A3 (en) | Sp1 and sp3 targeted cancer therapies and therapeutics | |
| CN108642176B (zh) | Part1作为乳腺癌诊断、治疗以及预后标志物的应用 | |
| GB0320648D0 (en) | Molecular marker | |
| ATE396262T1 (de) | Rna polymerase i transkriptionsfaktor tif-ia | |
| WO2005117974A3 (en) | Cancer treatment method by inhibiting mage gene expression or function | |
| Isozaki et al. | Acquired resistance to a new ALK inhibitor, alectinib in lung cancer | |
| ATE557089T1 (de) | Oligonukleotide zur hemmung und zum nachweis von humanen argonaute-proteinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |